Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

Investor Contact Information

Company

CollPlant Biotechnologies Ltd.
4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Transfer Agent

Computershare Trust Company, N.A.
150 Royall Street
Canton, Massachusetts 02021

Details

exploreCollPlant Ltd

4 Oppenheimer Street
P.O. Box 4132
Rehovot 7670104, Israel

local_phone+972 73 2325600
local_printshop+972 73 2325602

 
 

® 2024 CollPlant Biotechnologies Ltd. All rights reserved. Version: CPW 02-20

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.